Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular imaging 2011 Febbraio;55(1) > The Quarterly Journal of Nuclear Medicine and Molecular imaging 2011 Febbraio;55(1):81-90

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413


eTOC

 

ORIGINAL ARTICLES  


The Quarterly Journal of Nuclear Medicine and Molecular imaging 2011 Febbraio;55(1):81-90

lingua: Inglese

[18F]FDG-PET/CT monitoring early identifies advan-ced ovarian cancer patients who will benefit from prolonged neo-adjuvant chemotherapy

Martoni A. A. 1, Fanti S. 2, Zamagni C. 1, Rosati M. 1, De Iaco P. 3, D’Errico Grigioni A. 4, Castellucci P. 2, Quercia S. 1, Musto A. 2, Ricci Maccarini L. 3, Lopci E. 2, Bernardi A. 1

1 Unit of Medical Oncology, S.Orsola-Malpighi University Hospital, Bologna, Italy;
2 Unit of Nuclear Medicine, S.Orsola-Malpighi University Hospital, Bologna, Italy;
3 Unit of Gynaecology, S.Orsola-Malpighi University Hospital, Bologna, Italy;
4 Unit of Pathology, S.Orsola-Malpighi University Hospital, Bologna, Italy


PDF  


AIM: The most accepted standard duration of neoadjuvant chemotherapy (na-CHT) before debulking surgery for advanced ovarian cancer (AOC) is 3 courses. However a percentage of patients could benefit from additional courses. [18F]FDG-PET/CT monitoring during na-CHT could predict early pathological response and allow the delivery of an optimal na-CHT duration.
METHODS: Consecutive patients with AOC unsuitable for optimal upfront surgery and fit for na-CHT were monitored by FDG-PET/CT at baseline and after 3 and 6 courses of carboplatin-paclitaxel CHT. At the end of na-CHT patients were re-evaluated to undergo definitive optimal surgery (i.e. without post-surgical residual disease). Percentage changes in maximal standardized uptake value (∆-SUVmax) were compared with the pathological response. Only patients with pathological complete response (pCR) or minimal residual disease (pMRD) were considered as pathological responders (pR), while all the other cases were considered non-responders (NR).
RESULTS: Baseline FDG-PET/CT was abnormal in all 42 enrolled patients (median SUVmax 11, range 3-20). After 3 and 6 courses median SUVmax decreased to 3 (<2-21) and <2, i.e. value equal to normal surrounding tissues uptake (<2-17), respectively. After 3 courses, 17 (40%) patients presented ∆-SUVmax=100%, (i.e. SUVmax <2): 15 of them (88%) subsequently resulted pR and achieved no postsurgical residual disease at the end of na-CHT, while 2 (12%) were NR with postsurgical residual tumor ≤1cm. Out of 25 patients with ∆-SUVmax <100% after 3 courses, 6 (24%) were pR and 19 (76%) NR at the end of na-CHT.
CONCLUSION: Patients with AOC who present normalization of SUVmax after 3 courses of na-CT have a high likelihood of benefiting from 3 additional courses in order to obtain pCR or pMDR and receiving optimal surgery.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail

andrea.martoni@aosp.bo.it